tiprankstipranks
Advertisement
Advertisement

INmune Bio down 52% after primary endpoint of MINDFuL study not met

Shares of INmune Bio (INMB) are down $2.75, or 52%, to $2.58 in pre-market trading.

Claim 30% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1